Authorized purpose: RayStation 12A is configurable software for radiation therapy and medical oncology that proposes treatment plans from user input. Authorized users may use reviewed and approved plans to support treatment administration; the system includes image handling, contouring, treatment planning and optimization, dose calculation and evaluation, machine commissioning, treatment interfaces, and machine-learning segmentation or planning functions.
Clinical role
Imports patient imaging, supports registration and contouring, builds and optimizes treatment plans, calculates and evaluates dose, supports machine modeling and selected treatment interfaces, and exports reviewed and approved DICOM RT objects for downstream clinical use.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: The systems are not intended for long term storage of images or other patient data.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: RayStation 12A is configurable software for radiation therapy and medical oncology that proposes treatment plans from user input. Authorized users may use reviewed and approved plans to support treatment administration; the system includes image handling, contouring, treatment planning and optimization, dose calculation and evaluation, machine commissioning, treatment interfaces, and machine-learning segmentation or planning functions.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: CT, PET, and MR images transferred through DICOM; patient geometry and structures; treatment-machine and beam-model data; prescriptions, clinical goals, optimization objectives, and other user-entered planning parameters.
Who uses it?Intended users: Authorized intended users who review and approve proposed treatment plans before treatment use.
What does the software produce?Output: Proposed and approved treatment plans, dose distributions, structures, images, reports, machine and setup parameters, and DICOM RT exports for authorized review and downstream treatment workflows.
What is its most important limitation?Key limitation: The systems are not intended for long term storage of images or other patient data.
Clinical takeaway. Clinical role: RayStation 12A is configurable software for radiation therapy and medical oncology that proposes treatment plans from user input. Authorized users may use reviewed and approved plans to support treatment administration; the system includes image handling, contouring, treatment planning and optimization, dose calculation and evaluation, machine commissioning, treatment interfaces, and machine-learning segmentation or planning functions.
Evidence takeaway. Evidence from the reviewed source record: The exact-version evidence is strongest for technical validation and comparative plan quality, not patient outcomes. FDA-reviewed manufacturer tests covered dose-engine and treatment-technique changes, while an independent 59-plan comparison evaluated RayStation 12A CyberKnife plans. Additional independent product-family commissioning data support local QA design but cannot be assumed to represent 12A without version confirmation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
RayStation 12A is configurable software for radiation therapy and medical oncology that proposes treatment plans from user input. Authorized users may use reviewed and approved plans to support treatment administration; the system includes image handling, contouring, treatment planning and optimization, dose calculation and evaluation, machine commissioning, treatment interfaces, and machine-learning segmentation or planning functions.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Imports patient imaging, supports registration and contouring, builds and optimizes treatment plans, calculates and evaluates dose, supports machine modeling and selected treatment interfaces, and exports reviewed and approved DICOM RT objects for downstream clinical use.
CT, PET, and MR images transferred through DICOM; patient geometry and structures; treatment-machine and beam-model data; prescriptions, clinical goals, optimization objectives, and other user-entered planning parameters.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Proposed and approved treatment plans, dose distributions, structures, images, reports, machine and setup parameters, and DICOM RT exports for authorized review and downstream treatment workflows.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Professional radiation oncology and medical oncology environments performing treatment planning, machine commissioning, plan review, and approved-plan transfer or treatment-management workflows.
Authorized intended users who review and approve proposed treatment plans before treatment use.
Exact FDA submission
Checked 2026-09-19
The exact packet states that proposed plans are reviewed and approved by authorized intended users; it does not define the current role, qualification, or training wording.
The systems are not intended for long term storage of images or other patient data.
Exact FDA submission
Checked 2026-09-19
The exact packet states the storage boundary; the current acceptance, commissioning, lesion-detection, dose-check, export, and machine-learning limitations are not stated in this packet.
The exact-version evidence is strongest for technical validation and comparative plan quality, not patient outcomes. FDA-reviewed manufacturer tests covered dose-engine and treatment-technique changes, while an independent 59-plan comparison evaluated RayStation 12A CyberKnife plans. Additional independent product-family commissioning data support local QA design but cannot be assumed to represent 12A without version confirmation.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact-version evidence is strongest for technical validation and comparative plan quality, not patient outcomes. FDA-reviewed manufacturer tests covered dose-engine and treatment-technique changes, while an independent 59-plan comparison evaluated RayStation 12A CyberKnife plans. Additional independent product-family commissioning data support local QA design but cannot be assumed to represent 12A without version confirmation.
K222312 RayStation 12A nonclinical verification and validation
DesignManufacturer software verification and validation with water-tank, phantom, prior-engine, published-reference, competing-system, and independent Monte Carlo comparisons across changed treatment-planning functions
PopulationOcular planning, electron dose calculation, brachytherapy TG-43, automated field-in-field, Flexitron support, and other software changes; no patient cohort reported
Scopeexact submission
Tested versionRayStation 12A cleared in K222312
IndependenceSponsor or vendor study
K222312
FDA found the verification and validation adequate for substantial equivalence. The summary does not establish patient outcomes.
Target coverage was equivalent for brain cases and worse for vertebral cases; organ-at-risk sparing improved, conformity was lower, and optimization took longer. The authors reported no conflicts of interest.
Commissioning and validation of RayStation treatment planning system for CyberKnife M6
DesignIndependent single-center beam-model commissioning and phantom validation of collapsed-cone and Monte Carlo calculations for fixed, Iris, and multileaf collimators
PopulationCyberKnife M6 water-tank, homogeneous and heterogeneous phantom, irregular-field, off-axis, and patient-specific QA measurements
Scopeproduct family
Tested versionRayStation CyberKnife module; software release not reported
Sites1
IndependenceIndependent study
PMID 35856911
Most measured-versus-calculated differences were within plus or minus 1%, with a 3.2% maximum at 19.5 cm depth. One author held an unrelated Accuray grant.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-1105-2026 affects RayStation 12A and its first two service packs because calculated dose might not invalidate after geometry or material changes to certain empty, bolus, fixation, or support ROIs. FDA lists the recall as open and classified. FDA recall Z-2493-2025 includes RayStation 12A and its first two service packs. DICOM objects exported through the RayGateway interface to Accuray iDMS were not guaranteed to receive unique SOP Instance and Series Instance UIDs. FDA lists the recall as open and classified. FDA recall Z-1191-2025 includes RayStation 12A and its first two service packs. It concerns inconsistent interpretation of density uncertainty in robust optimization, robust evaluation, and perturbed-dose calculations for proton and light-ion plans using an HU-to-mass-density calibration curve. FDA lists the recall as open and classified. FDA recall Z-1750-2024 affects RayStation 12A builds 13.0.0.1547, 13.1.0.144, and 13.1.1.89 because the reported source-to-surface distance could be too high. FDA lists the recall as open and classified. FDA recall Z-1482-2024 includes RayStation 12A. It addresses a use error in which elemental silicon could be selected instead of silicone gel polymer as an implant material override, with potentially greater consequence for ion-beam planning. FDA lists the recall as open and classified.
FDA source
Exact product version
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
The FDA record names RayStation 12A builds 13.0.0.1547, 13.1.0.144, and 13.1.1.89. Verify installed build, correction status, and the vendor workaround.
RayStation 12A is explicitly included. Sites should verify material-assignment review controls and whether the affected material remains available in the installed release.
Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.
Public pricing
No public price for the exact RayStation 12A configuration was found. A 2025 vendor announcement reports a RMB 51 million RayStation order including a service contract for a Chinese carbon-ion center; it is a bundled product-family benchmark, not a 12A list price or a transferable quote.
These observations are not an exact-product procurement quotation. They are family, vendor, patient-charge, reimbursement, model, or unscoped records and are not comparable across dates, bundles, currencies, or units.
CNY 51000000
Price observation, scope not stated · total order including service contract · China
Observed 2025-03-04
Vendor-announced product-family order for an advanced carbon-ion, proton, and photon center. It is not a RayStation 12A list price, excludes unknown allocation across licenses and services, and should not be transferred to another institution or configuration.
CMS describes payment for professional and technical radiation therapy services, not a separate payment assigned to named treatment-planning software. The reviewed source does not support treating RayStation as independently reimbursed; local payer, contract, and service-line analysis remains necessary.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT, PET, and MR images transferred through DICOM; patient geometry and structures; treatment-machine and beam-model data; prescriptions, clinical goals, optimization objectives, and other user-entered planning parameters.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: RayStation 12A imports and exports DICOM and DICOM RT images, structures, plans, and dose objects and can exchange data with PACS, treatment delivery, and oncology workflow systems. The reviewed architecture uses patient, machine, and clinic Microsoft SQL databases.
Scope: Exact product version. Validate every DICOM service, transfer profile, object mapping, treatment-machine interface, database dependency, and failure-recovery path in the local environment.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: RayStation 12A supports Windows workstations connected to Microsoft SQL Server and DICOM systems, with documented desktop, centralized Citrix, shared application-server, and restricted virtual-machine patterns. The FDA summary permits standard desktop or remote virtualized use when remote behavior is verified equivalent to local use and states that RayStation is not intended for long-term image or patient-data storage.
Scope: Exact product version.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Proposed and approved treatment plans, dose distributions, structures, images, reports, machine and setup parameters, and DICOM RT exports for authorized review and downstream treatment workflows.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Proposed and approved treatment plans, dose distributions, structures, images, reports, machine and setup parameters, and DICOM RT exports for authorized review and downstream treatment workflows.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
RayStation 12A supports Windows workstations connected to Microsoft SQL Server and DICOM systems, with documented desktop, centralized Citrix, shared application-server, and restricted virtual-machine patterns. The FDA summary permits standard desktop or remote virtualized use when remote behavior is verified equivalent to local use and states that RayStation is not intended for long-term image or patient-data storage.
RayStation 12A imports and exports DICOM and DICOM RT images, structures, plans, and dose objects and can exchange data with PACS, treatment delivery, and oncology workflow systems. The reviewed architecture uses patient, machine, and clinic Microsoft SQL databases.
Exact product version
Checked 2026-09-02
Validate every DICOM service, transfer profile, object mapping, treatment-machine interface, database dependency, and failure-recovery path in the local environment.
The FDA summary describes licensing controls, checksums, and administrator-limited database access. RaySearch's 12A environment guide calls for role-based Active Directory groups, least privilege, encrypted SQL and backend communications, VPN or network segmentation for legacy DICOM, disk and database encryption where appropriate, encrypted backups, malware protection, account lockout, and controlled remote access.
Exact product version
Checked 2026-09-02
The environment guide warns that secure operation on Windows Server 2016 cannot be guaranteed after the end of NVIDIA R470 security support. Confirm the exact supported operating-system, GPU-driver, database, and patch matrix for the installed build.
The organization is responsible for ensuring that only authorized, appropriately trained planners and other qualified users operate RayStation 12A. Training should cover the configured clinical functions, plan review, machine and beam-model commissioning, automated segmentation review, dose-check independence, export verification, and applicable warnings.
RayStation 12A implementation guidance requires installation-specific acceptance and commissioning, independent dose verification, DICOM export checks, controlled software and hardware changes, database backup and maintenance, and monitoring of disk capacity, services, and processor resources. Automated-segmentation and machine-learning outputs remain subject to qualified-user review and local model commissioning.
Exact product version
Checked 2026-09-02
Local governance should also include incident review, backup-restoration tests, interface reconciliation, performance baselines, access review, vulnerability response, change control, and FDA recall surveillance.
The 12A environment guide documents local desktop, centralized Citrix, shared application-server, and restricted virtual-machine designs using Windows clients, Microsoft SQL Server, and supported NVIDIA GPUs.
exact product version · checked 2026-09-02
Size CPU, memory, GPU, storage, database, remote-display, and concurrency for the purchased modules and workload; confirm every component against the installed 12A build.
RayStation 12A imports CT, PET, and MR data and supports DICOM and DICOM RT exchange of images, structures, plans, and dose with connected clinical systems.
exact submission · checked 2026-09-02
The IFU requires verification that DICOM export completed successfully. Include object-level reconciliation and treatment-machine end-to-end tests in acceptance.
Role-based Active Directory groups separate administration, beam commissioning, plan approval, and machine-learning administration; the guide also describes least privilege, encrypted communications and storage, protected backups, malware controls, account lockout, VPN or segmentation for legacy DICOM, and controlled remote access.
exact product version · checked 2026-09-02
Translate vendor guidance into a site security design, access matrix, patch plan, vulnerability process, backup architecture, logging plan, and downtime procedure.
The IFU requires installation-specific acceptance after relevant hardware or software changes, local commissioning of machine-learning models, qualified-user review of automated segmentations, and genuinely independent dose verification.
exact product version · checked 2026-09-02
Create signed acceptance protocols for each modality, machine, energy, technique, dose engine, model, script, interface, and report used clinically.
RaySearch continues to market RayStation as a configurable treatment-planning platform spanning multiple treatment techniques and machine ecosystems and maintains versioned safety and performance documentation.
product family · checked 2026-09-02
Map all current commercial claims, support terms, upgrade paths, and optional modules back to the exact licensed 12A configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
24Fields reviewed
15Source classes checked
4Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 6 FDA recall candidates were manually reviewed: 5 published and 1 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 6 postmarket candidate records; 6 have been reviewed (5 published, 1 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor instructions for use, vendor technical documentation, vendor product page, peer reviewed publication, vendor pricing observation, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Authorized purpose: DeepContour uses deep-learning CT processing to generate editable organ contours and RTSTRUCT objects for selected adult radiation-treatment planning workflows, with quantitative statistics, registration, and three-dimensional visualization; it does not contour tumors.
Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.
Authorized purpose: RayStation and RayPlan releases covered by K240398 are configurable radiotherapy and medical-oncology software that proposes or supports treatment plans from user inputs, with authorized users required to review and approve plans before treatment.
Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.